Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or ...

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the Phase III ALLEGORY study of Gazyva ® ...

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to b ...

"Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Roche’s phase III ALLEGORY study of Gazyva/Gazyvaro in adults with systemic lupus erythematosus meets its primary endpoint: Basel Tuesday, November 4, 2025, 12:00 Hrs [IST] Roch ...

Basel: Roche has announced statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva/Gazyvaro (obinutuzumab) in adults with systemic ...